Investors
Synbio International, Inc. (OTC: SYIN) is a public company advancing AI-driven medical diagnostics and natural nutraceutical wellness products.
Company Profile
Synbio International, Inc. (formerly Natural Harmony Foods, Inc.) is a Florida corporation, incorporated January 14, 2002, trading on the OTC markets under the symbol SYIN. The company pursues two primary business lines: clinical validation of AI-driven facial analysis technology for detecting depression and other mental health conditions, and development of natural nutraceutical products targeting everyday wellness concerns such as stress and anxiety.
Synbio has entered clinical trial and strategic agreements with FacialDx Inc. to evaluate NIMS™, an AI-based facial analysis platform designed to objectively screen for major depressive disorder and PTSD. In August 2026 the company commenced revenue-generating operations with the launch of its Healing Force™ nutraceutical division and its first product, Healing Force™ Anxiety Relief.
Corporate Contact
Synbio International Inc.
30 N Gould St., Ste 5835
Sheridan, WY 82801
Phone: 307-278-1360
Investor & General Inquiries: (646) 359-4854
Twitter/X: @SYINofficial
Stock Chart
Quote and chart data provided by TradingView. For complete, current market data, view SYIN on OTC Markets.
Leadership
Giacinto Claudio Solitario
Chief Executive Officer & DirectorLeads Synbio’s overall corporate strategy, capital markets activity, and the company’s dual-track focus on AI-driven diagnostics and nutraceutical commercialization. Based in Perth, Western Australia.
Desiree Cain, CPA, MBA
Chief Financial Officer & DirectorMore than 25 years of corporate finance, accounting, and strategic growth experience. Leads financial operations, SEC and OTC Markets reporting, and corporate governance. Joined the company in September 2025.
Dr. Nick Vatakis, MD
Chief Medical Officer & DirectorPsychiatrist with nearly 30 years of clinical and research experience and principal investigator on more than 200 clinical trials. Oversees the design and execution of Synbio’s mental health screening clinical trials. Joined the company in September 2025.
| Class | Outstanding | Notes |
|---|---|---|
| Common Stock | 321,996,511 | Par value $0.001; 2,000,000,000 authorized |
| 2023 Series A Preferred | 200 | Each convertible into 10,000,000 common shares |
| 2023 Series B Preferred | 2 | Convertible into 4.99% of outstanding common |
| Holder | Control Person | Shares | % of Class |
|---|---|---|---|
| Pacific Capital Markets LLC | Zachory Logan | 22,000,000 | 7.0% |
| Synergy Management Group LLC | Benjamin Berry | 22,574,498 | 5.8% |
Corporate Information
Transfer Agent
Pacific Stock Transfer Co.
6725 Via Austi Parkway, Suite 300
Las Vegas, NV 89119
702-361-3033
Securities Counsel
Jeff Turner
JDT Legal PLLC
West Jordan, Utah
Accountant
Boladale Lawal & Co.
Brantford, Ontario, Canada
Company News
Read Synbio International’s latest press releases and corporate announcements.
View All NewsThe information on this page is a summary of Synbio International, Inc.’s (OTC: SYIN) public company profile and disclosures, compiled for investor convenience and sourced from the company’s OTC Markets disclosure filings. It does not constitute investment, legal, or financial advice and may not reflect the most current company data. Synbio International, Inc. is a shell company as defined under SEC regulations and has reported a stockholders’ deficit and going-concern uncertainty in its most recent financial disclosures. Investors should conduct their own due diligence and review the company’s complete, current filings on OTC Markets before making any investment decision.